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Abstract
We report results from a phase 2, randomized, double-blind, 2-period trial (48 weeks each) of domagrozumab and its open-label extension in
patients with Duchenne muscular dystrophy (DMD). Of 120 ambulatory boys (aged 6 to <16 years) with DMD, 80 were treated with multiple
ascending doses (5, 20, and 40 mg/kg) of domagrozumab and 40 treated with placebo. The primary endpoints were safety and mean change in
4-stair climb (4SC) time at week 49. Secondary endpoints included other functional tests, pharmacokinetics, and pharmacodynamics. Mean (SD) age
was 8.4 (1.7) and 9.3 (2.3) years in domagrozumab- and placebo-treated patients, respectively. Difference in mean (95% CI) change from baseline
in 4SC at week 49 for domagrozumab vs placebo was 0.27 (–7.4 to 7.9) seconds (p = 0.94). There were no significant between-group differences in
any secondary clinical endpoints. Most patients had ≥1 adverse event in the first 48 weeks; most were mild and not treatment-related. Median serum
concentrations of domagrozumab increased with administered dose within each dose level. Non-significant increases in muscle volume were observed
in domagrozumab- vs placebo-treated patients. Domagrozumab was generally safe and well tolerated in patients with DMD. Efficacy measures did
not support a significant treatment effect.
Clinicaltrials.gov identifiers: NCT02310763 and NCT02907619
© 2020 The Authors. Published by Elsevier B.V.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
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1. Introduction
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Duchenne muscular dystrophy (DMD) is an X-linked,
progressive, neuromuscular disorder caused by mutations in
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the DMD gene that result in a lack of dystrophin protein.
Dystrophin is critical for membrane integrity in skeletal and
cardiac muscle cells; its loss leads to skeletal and cardiac
muscle degeneration [1].
Myostatin (growth and differentiation factor 8) is a
member of the transforming growth factor-β superfamily and
a negative regulator of skeletal muscle mass [2,3]. Loss or
inhibition of myostatin in mdx mouse DMD models leads
to increased muscle mass, increased strength, and decreased
fat substitution and fibrosis [4-11]. This identifies myostatin
inhibition as a therapeutic target in multiple neuromuscular
disorders, including dystrophinopathies. Various strategies to
inhibit myostatin pharmacologically have been employed,
including neutralizing antibodies and adnexins, inhibitory
myostatin propeptides, myostatin receptor-Fc fusion protein,
follistatin the endogenous inhibitor of myostatin and
myostatin receptor blocking antibodies [12].
Domagrozumab,
a
humanized
recombinant
immunoglobulin (Ig)G1 antibody that binds to myostatin,
and inhibits its activity, was evaluated for treatment of DMD.
Wild-type and mdx mice treated with the murine equivalent
of domagrozumab RK35 had significant increases in body
weight, lean body mass, and grip strength. Cynomolgus
monkeys treated with domagrozumab showed significant
dose-dependent increases in lean muscle mass and muscle
volume, but no functional test was conducted [9].
A randomized phase 2 trial of domagrozumab
evaluated safety, efficacy, pharmacokinetics (PK), and
pharmacodynamics (PD) of multiple ascending doses of
domagrozumab in ambulatory boys with DMD. Patients who
completed the phase 2 trial were invited to participate in an
open-label extension (OLE) trial to evaluate the long-term
safety, efficacy, PK, and PD of domagrozumab. We report
results from both trials.
2. Materials and methods
2.1. Patients
Ambulatory boys aged 6 to <16 years with genetically
confirmed DMD were enrolled if they were able to perform
the 4-stair climb (4SC) in ≥2.5 but ≤12 seconds at screening,
and were receiving glucocorticosteroids for ≥6 months, with
a stable regimen for ≥3 months prior to guardians signing the
informed consent. Other inclusion criteria included adequate
hepatic and renal function.
Exclusion criteria included: underlying disposition for
iron accumulation or bleeding disorder; cognitive impairment
or behavioral issues that would have affected the conduct
of the study; history of surgery within 6 weeks, or
planned surgery during the study; any injury that may
impact function testing; compromised cardiac function (leftventricular ejection fraction [LVEF] <55% as determined
on cardiac MRI or echocardiogram [ECHO] screening);
current or prior treatment with anti-myostatin; exon skipping;
nonsense mutation–targeted therapies; or treatment with
utrophin modifiers within the preceding 30 days or for >30
days in total.
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Patients were included in the OLE if they completed the
phase 2 trial through week 97, had adequate hepatic function,
glutamate dehydrogenase (GLDH) ≤20 units/L, iron content
estimate within the normal range on a liver MRI, and provided
consent.
2.2. Standard protocol approvals, registrations, and
participant consent
A phase 2 trial (B5161002; ClinicalTrials.gov:
NCT02310763) and an OLE trial (Study B5161004;
ClinicalTrials.gov: NCT02907619) were investigated. Both
studies were conducted in accordance with legal and
regulatory requirements, as well as the general principles set
forth in the International Ethical Guidelines for Biomedical
Research Involving Human Subjects, guidelines for Good
Clinical Practices, and Declaration of Helsinki. The protocols,
any amendments, and informed consent/assent documents
were approved by the institutional review board or ethics
committee at each study center. Parent or legal guardians
provided written, informed consent prior to any study-specific
activity being performed.
2.3. Study design and treatment
The phase 2 trial was a randomized, 2-period, doubleblind, placebo-controlled, multiple ascending dose (5, 20, and
40 mg/kg) study of domagrozumab vs placebo in ambulatory
boys with DMD. The trial was conducted between November
24, 2014 and November 23, 2018, in patients from 31 sites
in 8 countries.
Patients were stratified by 4SC time (≤ or >8 seconds) at
baseline and randomly assigned to 1 of 3 sequence groups.
Randomization into sequence groups (treatment assignment)
was generated using an Interactive Response Technology
System by unblinded, dispensing personnel. The first exposure
to domagrozumab was a within-patient dose escalation (5, 20,
and 40 mg/kg) for 48 weeks; subsequent exposure continued
at 40 mg/kg, determined to be the maximum tolerated dose in
the dose escalation period, in both the phase 2 and OLE trials.
In Sequence 1, domagrozumab within-patient dose escalation
(period 1) was followed by domagrozumab in weeks 49–96
(period 2). In Sequence 2, domagrozumab within-patient dose
escalation in the first 48 weeks was followed by placebo
in weeks 49–96. In Sequence 3, placebo in the first 48
weeks was followed by domagrozumab within-patient dose
escalation in weeks 49–96 (Fig. 1). Patients received treatment
for 96 weeks, i.e., two treatment periods of 48 weeks each,
without pause between periods.
At each dose level, the study drug was administered over 2
hours by IV infusion every 4 weeks for a total of 16 weeks (4
doses; Fig. 1). At the initiation of the phase 2 trial, individual
dose escalation for each patient occurred after review of all
available safety data through the planned fourth dose within
each dose level until the External-Data Monitoring Committee
agreed, after a number of patients had completed the first
48 weeks of the phase 2 trial, that dose escalation could
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Figure 1. Phase 2 trial (Study B5161002) design. OLE, open-label extension (B5161004).

proceed without individual safety review for the remainder
of the study. Patients in the OLE trial were to be treated with
domagrozumab every 4 weeks for up to 4 years.
The phase 2 trial and the OLE trial were terminated in
August 2018 after the analysis of phase 2 trial data (described
below) showed there was no significant treatment effect vs
placebo in the primary efficacy endpoint (4SC) and other
functional endpoints.
2.4. Procedures and outcomes
The primary objectives of the phase 2 trial were safety
and tolerability of multiple ascending, repeat IV doses of
domagrozumab and efficacy at 49 weeks based on an
observed mean change from baseline in 4SC time (assessed
every 8 weeks) in patients treated with domagrozumab vs
placebo. The primary objective of the OLE trial was longterm safety of domagrozumab in boys with DMD.
Safety assessments in the two trials included: frequency
and severity of incidence of abnormal and clinically relevant
laboratory findings; physical examinations; vital signs; EKG,
LVEF by cardiac MRI or ECHO (determined by site
preference); liver MRI R2∗ monitoring iron accumulation
[13]; and the Columbia Suicide Severity Rating Scale.
AEs of special interest included, liver iron accumulation,
precocious puberty and epistaxis (seen with ACE-031, a less
selective myostatin inhibitor) [14]. GLDH, a liver-specific
injury biomarker was added to monitor for drug-induced liver
injury in addition to transaminases, which are elevated from
dystrophic muscle in DMD.
The North Star Ambulatory Assessment (NSAA) [15-17],
range of motion using goniometry [18], Performance of Upper
Limb (PUL) [19,20], 6-minute-walk distance (6MWD) [21],
pulmonary function based on forced vital capacity (FVC)
using spirometry [17,22], and strength assessed by hand-held
myometry were conducted every 8 weeks in the phase 2
trial and every 24 weeks in the OLE. Secondary functional

endpoints were assessed as mean change from baseline vs
placebo during the first 49 weeks in the phase 2 trial. In the
OLE trial, all functional assessments, including 4SC time,
were assessed as change from overall baseline (beginning of
phase 2) and change from OLE baseline. In both studies,
change from baseline for all functional assessments was also
analyzed by sequence group.
To characterize long-term effect following 96 weeks
treatment with domagrozumab, data were compared with
a historical control group derived from the Cooperative
International Neuromuscular Research Group (CINRG) DMD
natural history database [23,24]. The control cohort from
CINRG was selected to closely match the population for
age, glucocorticosteroid usage, baseline 4SC time, ambulatory
status, and baseline LVEF ≥55%. The historical control
group was first compared with Sequence 3 (placebo group
in the phase 2 trial) by evaluating the mean change from
baseline at week 49 to assess similarities between the two
untreated populations. The historical control group was then
compared to Sequence 1 to evaluate the mean change from
baseline at week 97. Matched control data were selected
by comparing the baseline criteria to all available visits
in the CINRG database. Some patients in the historical
control group had multiple eligible baseline visits eligible
for comparison matching enrollment criteria (with a followup visit 96 ± 9 weeks later), and in these cases their
baseline visit was chosen at random for the week 97 analysis.
The same approach was used for the week 49 analysis for
historical control patients with eligible baseline visits and
follow-up visits 48 ± 4 weeks later.
Secondary PD endpoints specific to the phase 2 trial
included changes in thigh muscle volume on MRI (every 12
weeks) [25,26] and modulation of myostatin in serum (every
4 weeks). A prespecified subgroup analysis was performed to
assess treatment effects in a subgroup of patients with baseline
4SC ≥3.5 to ≤8 seconds who may be more rapidly declining
with lower variability over a 1-year period [27].
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In the OLE trial, pulmonary function tests also included
forced expiratory volume in 1 second and peak expiratory
flow rate. Ambulatory status was reviewed at each visit in
the OLE trial. Loss of ambulation in OLE was defined as the
inability to walk ≥10 meters unassisted and without braces,
and in the historical control group as daily wheelchair use.
The functional health status as assessed by the Pediatric
Outcomes Data Collection Instrument (PODCI) was an
exploratory endpoint, which was completed by parents or
caregivers of children aged ≤10 years; the adolescent selfreport version was completed by patients ≥11 years old [28].
Other clinical outcomes assessments in the OLE assessed
the long-term effects of domagrozumab on: (i) health-related
quality of life using the EuroQoL–5 Dimensions 3 Levels
(EQ-5D-3L) and healthcare resource utilization in boys with
DMD; and (ii) caregiver burden due to child’s DMD, using
the Zarit Burden Interview (ZBI) and work productivity
and activity impairment using the Work Productivity and
Activity Impairment questionnaire adapted for the caregiver
(WPAI:CG) [29].
Blood samples for PK, anti-drug antibody (ADA), and
neutralizing antibody analyses were collected during the
96 weeks of the study and were analyzed using validated
analytical methods. PK parameters included maximum serum
concentration (Cmax ); time to Cmax (Tmax ); trough (predose)
serum concentration (Ctrough ); serum concentration at the
end of planned 2-hour infusion (C2 ); area under the serum
concentration–time curve over the dosing interval τ (AUCτ ),
where τ = 4 weeks (672 hours); and the average serum
concentration over the dosing interval (Cav ). Cmax , Tmax , and
Ctrough were derived from serum of all patients treated with
domagrozumab. AUCτ , Cav , and drug clearance were derived
from patients with additional PK sampling who received
domagrozumab in the first 48 weeks.
2.5. Statistical analysis
The planned sample size of 105 patients for the phase
2 trial was designed to detect a 2.5-second difference in
change from baseline to week 49, in 4SC time, between
domagrozumab and placebo treatment, assuming a common
SD of 4.0 seconds with 80% power at α = 0.05 (2-sided),
a 2:1 treatment allocation, 1 interim analysis for futility
prior to the primary analysis, and 10% attrition rate. All
analyses were based on the full analysis set, which included
all randomized patients who received ≥1 dose of study drug.
Patients assigned to Sequence 1 and Sequence 2 (i.e., treated
with domagrozumab through week 48) were analyzed together
and compared with patients in Sequence 3 (i.e., treated with
placebo through week 48).
In the phase 2 trial, the primary efficacy endpoint,
change from baseline in 4SC time, was analyzed using
a longitudinal mixed-effects model for repeated measures
(MMRM). The baseline result, treatment, time, and treatment
by time interaction, were included as fixed effects in the
model. Patients were included as a random effect and the
model was fit with an unstructured covariance for the repeated
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measures. The distribution of the 4SC time was assumed to
be right-skewed. Negative values in 4SC mean improvement.
Transformations (including log transformation) of the 4SC
time were evaluated to ensure the normality assumption was
met. Contrasts were created to estimate the differences in
change from baseline, in 4SC time, at the end of each dosetreatment level for the first 48 weeks (weeks 17, 33, and 49).
The final analysis of the primary endpoint was performed at
week 49, though data continued to be collected through week
97.
Missing data were handled using maximum likelihood
techniques for MMRM. This analysis is unbiased under
the assumption of missing at random when the model
assumptions hold (i.e., missingness is unrelated to the missing
values, had they been observed). Patients who lost the
ability to complete a functional assessment and/or ambulate
were assumed to be missing not at random. Additional
imputation methods to assess the sensitivity of the analysis to
missing not at random data were also performed and included
completer analyses (i.e., patients who reached week 49), and
transforming time to complete a functional assessment to
velocity, so that patients with a missing time were assumed
to have a velocity of zero.
Secondary endpoints were analyzed using the same
longitudinal mixed model as described for the primary
endpoint. In the prespecified subset of patients with an
anticipated rapid disease decline (>1 year), the mean change
on functional tests from baseline vs placebo was evaluated.
MRI of the right thigh was acquired without the use of
contrast, using a proton density weighted spin-echo sequence
with 5 mm slices and 0 mm gap to cover the entire
thigh (knee-to-hip). Imaging data were sent to BioTelemetry
Research (Cardiocore & VirtualScopics, Rochester, NY) for
quality evaluation and analysis. In addition to thigh muscle
volume measurements, muscle volume index measurements
were calculated based on whole thigh MRI images. Muscle
volume index is a measure of the fraction of the total thigh
tissue that is lean muscle[30] and was calculated as follows:
(muscle volume / [muscle volume + inter/intra-muscular fat
volume]) × 100
PK population for serum concentration included all
patients who received ≥1 dose of domagrozumab and had
≥1 concentration value reported. The population for PK
parameters included all patients who received ≥1 dose of
domagrozumab and had ≥1 PK parameter calculated. The
population for myostatin serum concentration included all
patients who had ≥1 concentration value reported.
3. Results
3.1. Patients
Of 162 patients with DMD who were screened for study
entry, 121 enrolled and 120 were treated (Supplementary
material – Fig. S1). Key reasons for screening failure were
4SC <2.5 seconds and LVEF <55%. Mean age at baseline
was 8.7 (range, 6–15) years. The mean (SD) weight in
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Table 1
Patient demographics and baseline characteristics by sequence group.
Sequence 1
n = 41
Age, mean (SD), year
8.3 (1.9)
Race, n (%)
White
33 (80.5)
Black
1 (2.4)
Asian
6 (14.6)
Other
1 (2.4)
Weight, mean (SD), kg
29.9 (8.5)
Range
14.8–48.8
BMI, mean (SD), kg/m2
19.4 (3.9)
Height, mean (SD), cm
123.2 (8.0)
Glucocorticosteroids usage, n (%)
Deflazacort
25 (61.0)
Prednisone or prednisolone 16 (39.0)
4SC time, s
Mean (SD)
5.2 (2.5)
6MWD, meters
Mean (SD)
357.9 (99.0)
NSAA: Time to complete 10-m run/walk, s
Mean (SD)
6.5 (1.9)
NSAA: Time to stand from supine, s
Mean (SD)
7.1 (5.1)
NSAA score, s
Mean (SD)
19.5 (6.7)
PUL: overall score
Mean (SD)
66.8 (4.0)

Sequence 2
n = 39

Sequence 3
n = 40

8.5 (1.5)

9.3 (2.3)

33 (84.6)
0
5 (12.8)
1 (2.6)
30.3 (8.8)
16.4–50.1
19.5 (3.8)
123.6 (8.9)

35 (87.5)
1 (2.5)
4 (10.0)
0
35.3 (14.4)
19.0–86.4
20.7 (5.8)
128.9 (9.3)

20 (51.3)
19 (48.7)

25 (62.5)
15 (37.5)

5.0 (3.3)

5.3 (2.8)

374.0 (99.2)

350.8 (84.9)

5.7 (1.3)

6.4 (1.8)

7.7 (5.9)

7.7 (3.8)

21.5 (7.1)

20.2 (7.2)

67.0 (5.2)

67.1 (3.2)

4SC = 4-stair climb; BMI = body mass index, NSAA = North
Ambulatory Assessment; PUL = performance of upper limb.

Star

Sequence 3 (35.3 [14.4] kg) was higher than that in Sequence
1 (29.9 [8.5] kg) and Sequence 2 (30.3 [8.8] kg), which
was driven by two patients with weights of 86.4 kg and
81.8 kg each. Most patients were on a high daily dose
of glucocorticosteroids. Other demographics and baseline
characteristics were comparable across all sequence groups
(Table 1).
By week 49, seven patients discontinued from the phase 2
trial because of: unwillingness to participate in study (n = 3),
lost to follow-up (n = 1), AE (n = 1), and other reason (n = 2).
By week 97, 48 patients discontinued due to early termination
of the trial, 65 patients completed 96 weeks of the phase
2 trial, and 59 were treated in the OLE. All 59 patients
discontinued the OLE: 55 because of early termination of
the trial, 1 death (unrelated to study drug), 1 moved away
from the site, and 2 no longer willing to participate.

3.2. Safety
In the first 48 weeks of the phase 2 trial, 115 patients
experienced all-causality, treatment-emergent AEs (TEAEs;
Table 2). Five patients had 6 serious AEs (appendicitis and
anxiety, superior sagittal sinus thrombosis, femur fracture,
troponin increased, and femoral neck fracture); none were
considered drug-related. TEAEs by sequence in the phase 2
weeks 49–96 and OLE were similar to those in the first 48
weeks.

Table 2
Treatment-emergent, all-causality AEs, by Sequence and total in the first 48
weeks of the Phase 2.
No. of Patients, Phase 2a , b

Sequence 1 Sequence 2 Sequence 3 Total

Evaluable for AEs
Number of AEsb
AEs
Serious AEs
Severe AEs
Discontinued due to AEs
Dosing temporarily
discontinued due to AEs

41
263
39
1
2
1c
3

39
222
38
1
3
0
5

40
286
38
0
2
0
8

120
771
115
2
7
1c
16

Includes all data collected since the first dose of study drug in the first 48
weeks. AE baseline was defined as the last predose assessment prior to each
individual dose level. If the same patient in a given sequence had more than
one occurrence in the same preferred-term event category, only the most
severe occurrence was taken.
AE = adverse event.
a Medical Dictionary for Regulatory Activities (v21.0) coding applied.
b Except for the Number of AEs, patients are counted only once per
sequence in each row.
c Discontinuation due to serious AE (exacerbation of pre-existing anxiety).

In the OLE trial, all 59 patients had all-causality TEAEs,
4 had severe AEs, and 1 discontinued due to AE of lethal
fat embolism syndrome from tibial fracture. Five patients had
8 serious AEs (ileus paralytic and volvulus, fat embolism,
appendicitis, seizure, angina pectoris, and troponin increase);
none were considered drug-related.
There were no safety concerns identified for all AEs
of special interest, including epistaxis, precocious puberty,
or hepatic iron accumulation. GLDH >3 × upper limit of
normal (ULN) was observed in one patient each in the
domagrozumab and placebo groups. Elevation of GLDH
<3 × ULN was comparable between the two treatment
groups.
There was no difference between domagrozumab- and
placebo-treated patients in cardiac TEAEs, and no consistent
pattern of change in LVEF related to cardiac TEAEs between
treatment groups. At week 97, mean changes (SD) from
baseline in LVEF by both cardiac MRI and ECHO were –
3.9 (5.6), –1.6 (5.4), and –0.9 (6.2) for Sequences 1, 2, and
3, respectively. Patients in Sequence 1 who had exposure to
domagrozumab for 96 weeks had a nominally greater but
non-statistically significant decrease in LVEF compared with
Sequences 2 and 3, where exposure to domagrozumab was
limited to 48 weeks. Elevations in cardiac troponin I were
not sustained or associated with clinical symptoms. The AE
of troponin increased was reported as related to treatment
in 3 patients (2 treated with placebo and 1 treated with
domagrozumab) in the first 48 weeks.
3.3. Efficacy
The primary endpoint of mean change in 4SC time at
week 49 was not met in the phase 2 trial (Fig. 2). Based
on the MMRM analysis, the difference in mean change in
4SC time from baseline to week 49 for domagrozumab vs
placebo was 0.27 seconds (95% CI: –7.4, 7.9; p = 0.94). All
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Domagrozumab vs Placebo
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Week 9

Week 17

Week 25

Week 33

Week 41

Week 49

Visit
Figure 2. Mean (95% CI) change from baseline on 4SC for domagrozumab vs placebo at week 49. 4SC, 4-stair climb.
Table 3
Primary and sensitivity analyses for 4SC in phase 2 trial at week 49.
Mean Change From
Baseline to Week 49

Domagrozumab, Sequence
1&2 Combined, Mean (SE)

Placebo, Mean (SE)

Difference, Domagrozumab
vs Placebo, Mean (95% CI)

p Value

4SC, MMRM, s
Log-transformed 4SC,
MMRM, log s
Log-transformed 4SC
changes, MMRM, %
Completera analysis 4SC,
MMRM, s
4SC velocity, MMRM, 4
stairs/s
4SC subgroup: baseline 4SC
≥3.5 & ≤8 s
Full analysis set
Completera analysis
PPAS of 4SC, s
Wilcoxon test of 4SC, rank
score
Wilcoxon test of velocity
4SC, rank score

8.28 (2.15)
0.30 (0.05)

8.01 (3.03)
0.40 (0.08)

0.27 (–7.40, 7.90)
–0.10 (–0.28, 0.09)

0.94
0.29

–

–

–9.4 (–24.7, 8.9)

0.29

1.88 (0.74)

2.75 (1.04)

–0.87 (–3.42, 1.67)

0.50

–0.05 (0.01)

–0.06 (0.01)

0.02 (–0.01, 0.05)

0.30

3.62 (0.94)
1.53 (0.62)
7.03 (2.02)
45.53

3.53 (1.16)
2.49 (0.76)
7.77 (2.79)
52.86

0.094 (–3.08, –3.27)
–0.97 (–2.9, 1.0)
–0.75 (–7.98, 6.49)
–7.33

0.95
0.33
0.83
0.22

59.23

52.59

6.64

0.31

4SC = 4-stair climb; MMRM = mixed model for repeated measures; PPAS = per protocol analysis set.
a Completer is defined as patient with 4SC data at week 49. Patients with missing 4SC values at week 49 have been excluded.

sensitivity analyses showed directionally favorable but nonstatistically significant results with domagrozumab (Table 3).
There were no significant differences in the mean change from
baseline on the 4SC between the domagrozumab and placebo
in the prespecified subgroup, based on baseline 4SC time at
all measurements (Table 3).
The mean change in 4SC at week 49 in the placebo
group was similar to the historical control group (difference,
0.211; 95% CI: –2.835, 3.257; p = 0.8908). These findings
suggest the historical control dataset can serve as an adequate
control group for the analysis of 4SC at week 97. There was
no significant difference in mean change in 4SC time from
baseline to week 97 between Sequence 1 and the historical

control group; the difference using MMRM was 0.819
seconds (95% CI: –1.451, 3.090; p = 0.4748). Also, there was
no significant change in 4SC time between Sequence 1 and
the historical control group from overall baseline to week
170 in the OLE trial (difference, 10.57; 95% CI: –1.313,
22.463; p = 0.0811). In the OLE, there was a mean increase
from overall baseline to week 146 of 6.784 seconds (95%
CI: 0.749, 12.819) observed in the 4SC time among 15/59
evaluable patients across the 3 treatment sequences.
No significant treatment differences were found for the
analysis of FVC, percent predicted FVC, NSAA, 6MWD,
myometry-based muscle strength, or PUL (Table 4). There
was no significant difference in time to loss of ambulation
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Table 4
Key secondary and exploratory endpoints in Phase 2 trial at Week 49.
Mean Change From
Baseline to Week 49

Domagrozumab, Sequence
1&2 Combined, Mean (SE), n

Placebo, Mean (SE), n

Difference, Domagrozumab
vs Placebo, Mean (95% CI)

P Value

FVC, MMRM, L
Predicted FVC, MMRM, %
NSAA
Total score
Time to complete 10 m
run/walk, MMRM, s
Time to stand from supine,
MMRM, s
6MWD, MMRM, m
Myometry-based muscle strength
Right knee extension
Left shoulder abduction
Right shoulder abduction
PUL, overall score
PUL, shoulder level score
PUL, middle level score
PUL, distal level score
PODCI
Transfer and basic
mobility core scale
Sports and physical
functioning
Pain/comfort
Happiness
Global functioning

0.11 (0.03), 74
–0.24 (2.02), 74

0.15 (0.04), 38
0.07 (2.65), 38

–0.042 (–0.12, 0.04)
–0.31 (–6.08, 5.46)

0.30
0.92

–3.6 (0.7), 73
1.23 (0.23), 58

–5.2 (0.9), 37
1.20 (0.33), 26

1.6 (–0.5, 3.8)
0.034 (–0.67, 0.73)

0.13
0.92

3.08 (1.08), 51

2.42 (1.43), 25

0.667 (–6.06, 7.40)

0.71

–58.0 (9.3), 61

–56.5 (12.7), 30

–1.5 (–30.0, 27.0)

0.92

-1.13 (0.29), 75
–0.32 (0.18), 74
–0.30 (0.23), 74
–1.4 (0.4), 74
–1.0 (0.3), 75
–0.4 (0.2), 74
–0.1 (0.1), 74

-0.98 (0.39), 37
–0.30 (0.24), 37
0.14 (0.31), 37
–1.3 (0.5), 38
–1.1 (0.4), 38
–0.2 (0.3), 38
–0.2 (0.1), 38

–0.15 (–1.01, 0.71)
–0.02 (–0.57, 0.52)
–0.44 (–1.17, 0.29)
0 (–1.3, 1.2)
0.1 (–0.9, 1.1)
–0.2 (–0.8, 0.4)
0.2 (–0.1, 0.5)

0.73
0.93
0.23
0.94
0.83
0.51
0.27

–11.1 (2.00), 73

–15.1 (2.75), 35

4.1 (–2.02, 10.13)

>0.05

–11.1 (2.03), 73

–13.9 (2.79), 35

2.8 (–3.17, 8.86)

> 0.05

–4.1 (2.47), 73
–9.5 (2.36), 73
–7.7 (1.60), 73

–8.1 (3.38), 35
–10.8 (3.24), 35
–11.5 (2.20), 35

4.0 (–3.69, 11.63)
1.4 (–5.87, 8.60)
3.8 (–1.15, 8.71)

>0.05
>0.05
>0.05

6MWD = 6-minute-walk distance; FVC = forced vital capacity; MMRM = mixed model for repeated measures; NSAA = North Star Ambulatory Assessment;
PODCI = Pediatric Data Collection Instrument; PUL = performance of upper limb.

from the OLE baseline throughout the OLE trial between
Sequence 1 and the historical control group (p = 0.3011). In
the OLE, 17 (of 59) patients experienced loss of ambulation
(Sequence 1: n = 3, Sequence 2: n = 7, Sequence 3:
n = 7).
3.4. Clinical outcomes assessments
Decreases from overall baseline for the PODCI parentreported scores were observed in all 5 items and the Global
Functioning Scale over the course of both trials (Table 4).
The least decrease from overall baseline was seen for the
pain/comfort core scale (mean change at week 146, –6.3;
95% CI: –13.6, 1.1). The greatest decrease from overall
baseline was for transfer and basic mobility core scale (mean
change at week 146, –21.1; 95% CI: –32.6, –9.7). A change
from baseline in the adolescent self-report measure was
not performed due to the limited number of baseline visit
assessments.
There was no change in general health status (EQ-5D-3L,
EQ-5D-Youth) and health resource utilization from baseline
of the OLE trial throughout its course. There was no change
in caregiver burden from OLE baseline through the end of
the OLE (mean change in ZBI total score, –0.6; 95% CI: –
3.4, 2.3, among 18/59 evaluable patients at week 49). Impact
on work productivity and activity impairment was observed

from OLE trial baseline throughout the course of the OLE
trial in all 4 items of the WPAI:CG: mean change at week
49 was 2.3 (95% CI: –2.632, 7.224) for percent worktime
missed, 7.1 (95% CI: 0.2, 14.1) for percent impairment while
working, 9.2 (95% CI: 2.496, 15.871) for percent overall work
impairment, and 8.9 (95% CI: 1.1, 16.7) for percent activity
impairment.
3.5. Pharmacokinetics
Median serum concentrations of domagrozumab increased
with increasing dose level for patients within each dose level
(first 48 weeks and weeks 49–96) following domagrozumab
IV administration at 5, 20, and 40 mg/kg. Following repeated
administration at 40 mg/kg, median serum concentrations
remained generally constant for patients during weeks 49–
96 in Sequence 1. Ctrough values generally increased from
the first dose of domagrozumab through the last dose,
within each dose level during escalation. The Ctrough values
appeared in steady-state by the last dose of within-patient
dose escalation in all sequences and remained at steady-state
with domagrozumab 40 mg/kg in Sequence 1, weeks 49–
96. PK parameters for domagrozumab following the first and
last dose administration at each dose level for patients, with
additional PK sampling in the first 48 weeks, (Sequences 1
and 2) are described in Table 5.
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Table 5
PK parameters of domagrozumab for patients with additional PK sampling in the first 48 weeks (Sequences 1 and 2).
Domagrozumab Parameter Summary Statisticsa by Week

Parameter, units

5 mg/kg IV

20 mg/kg IV

40 mg/kg IV

Week 1

Week 13

Week 17

Week 29

Week 33

Week 45

2
21700, 31300

2
29500, 39800

2
102000, 139000

C2 , μg/mL
Cav , μg/mL
Cmax , μg/mL
Ctrough , μg/mL
Tmax , hr
CL, mL/hr/kg
Weeks 49–96d
N, n, n1, n2b
AUCτ , μg•hr/mL
C2 , μg/mL
Cav , μg/mL
Cmax , μg/mL
Ctrough , μg/mL
Tmax , hr

119, 147
32.3, 46.6
119, 147
NR
2.08, 2.25
NC

113, 181
43.9, 59.2
115, 181
20.6, 22.6
2.13, 4.42
0.126, 0.17

410, 574
151, 207
410, 574
20, 29.6
2.15, 2.17
NC

2
129000,
175000
522, 680
192, 261
522, 680
100, 127
2.05, 2.08
0.114, 0.155

2
216000,
273000
870, 1160
322, 406
870, 1160
107, 116
2.13, 2.17
NC

2
285000,
382000
1140, 1160
424, 568
1160, 1220
193, 257
2.17, 5.67
0.105, 0.14

5, 5, 5, 5
24670 (31)
126.2 (12)
36.72 (31)
126.2 (12)
NR
2.3 (2.03–2.42)

5, 5, 5, 5
40070 (21)
158.2 (18)
59.63 (21)
158.2 (18)
28.71 (23)
2.55 (2.17–2.73)

4, 4, 3, 4
117700 (8)
499.5 (7)
175.3 (8)
501.6 (7)
28.09 (14)
2.2 (2.08–6.47)

NC

0.1247 (21)

NC

4, 4, 4, 4
293200 (21)
1221 (15)
436.3 (21)
1227 (16)
147.9 (20)
2.39
(2.23–5.15)
NC

–
–
–
–
–
–
–

CL, mL/hr/kg

5, 5, 4, 4
183000 (14)
683 (12)
272.1 (14)
687.5 (14)
135.2 (20)
2.15
(2.08–2.5)
0.1092 (14)

nb , c

First 48 weeks,
Nb
AUCτ , μg•hr/mL

–

AUCτ = area under the serum concentration–time curve during a dosing interval; C2 = serum concentration at the end of planned 2 hr infusion; Cav = average
drug concentration; CL = drug clearance; Cmax = maximum serum concentration; Ctrough = trough serum concentration; CV = coefficient of variation; NC = not
calculated; NR = not reported; Tmax = time to reach maximum serum concentration.
a Summary statistics were not presented if fewer than 3 patients have reportable parameter values. The minimum and maximum were reported.
b N = number of patients in the treatment group in the indicated population; n = number of patients contributing to the summary statistics; n1 = number of
patients contributing to the summary statistics for AUCτ , CL, and Cav ; n2 = number of patients contributing to the summary statistics for Cmax and Tmax .
c Individual patient values were presented for n<3.
d Geometric mean (geometric %CV) for all except: median (range) for T
max . Geometric means not presented for Ctrough when individual values include 0.

3.6. Serum myostatin pharmacodynamics and imaging
biomarkers
An increase in baseline total serum myostatin
(domagrozumab-bound
and
free
myostatin)
post
domagrozumab treatment was observed for all the treatment
sequences. Total serum myostatin Ctrough levels were slightly
higher for all dose levels compared with placebo. There were
no apparent dose-specific trends observed for total myostatin
Ctrough levels.
The MMRM analysis showed no significant differences
between domagrozumab and placebo in mean percent change
from baseline on thigh muscle volume measures on MRI at
weeks 17, 33, and 49. This analysis includes measurement
of whole thigh muscle volume and whole thigh inter/intramuscular fat volume. Although there were no significant
differences in mean percent change from baseline, for
both muscle volume and muscle volume index, there were
directionally favorable differences between domagrozumab
and placebo; the differences (domagrozumab to placebo) at
weeks 17, 33, and 49, respectively, were 2.19%, 2.11%, and
2.86% for whole thigh muscle volume and 0.76%, 1.76%, and
1.98% for thigh whole muscle volume index.

3.7. Immunogenicity
Based on all immunogenicity samples tested in the phase
2 trial, only 1 sample in one patient in Sequence 3 had
a positive ADA titer (≥1.88), which was at week 65; the
patient’s subsequent samples were negative for ADA. No
participants in the OLE trial tested positive for ADA.
4. Discussion
Multiple ascending, monthly doses of domagrozumab at
5, 20, and 40 mg/kg were generally safe and well tolerated.
The phase 2 trial did not meet its primary efficacy endpoint
of mean change from baseline in 4SC time at week 49.
Sensitivity analyses all showed directionally favorable, but
non-statistically significant and not clinically meaningful
treatment effects with domagrozumab vs placebo.
Potential etiologies for the disappointing outcome in this
trial include different PD of domagrozumab in humans versus
mice, recent finding of marked reduced baseline myostatin
levels in patients with DMD suggesting a more severe
downregulation of the myostatin pathway in patients with
DMD compared with mdx mice, and/or other ligands not
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impacted by domagrozumab playing an important role in
primate muscle mass regulation [31]. Another potential reason
for lack of efficacy relates to the recent finding, identified
after the protocol initiation, that in the mdx mice, daily
glucocorticosteroids administration were shown to interfere
with potential benefits associated with myostatin inhibition
[32]; however, the murine homolog of domagrozumab
mRK35, produced similar increases in body weight and
lean muscle mass in control and mdx mice with and
without prednisolone treatment [33]. With the more recent
negative clinical results from other myostatin inhibitors (e.g.,
bimagrumab, ACE-083, RG6206) in multiple muscle wasting
diseases, a comprehensive review of myostatin inhibition as
a target for human muscle wasting diseases is warranted.
The majority of patients experienced ≥1 TEAE. The
incidence of AEs was comparable between domagrozumab
and placebo, and among the 3 dose levels of domagrozumab.
AEs were mostly mild and moderate and consistent with those
reported previously in patients with DMD [14,34-36]. None
of the reported serious AEs were considered drug-related.
Preliminary data showed numerically greater LVEF decline
with domagrozumab exposure at weeks 97 vs 49. The final
data showed decrease in risk, but although the quantitative
difference in LVEF was neither statistically different nor
considered clinically meaningful, the event was classified
as a potential risk, with the implication for additional
monitoring.
The 4SC functional test was selected as the primary
efficacy endpoint for this trial based on results of prior
glucocorticosteroid trials [37-39], and because it is considered
a reliable measure of motor function [27,40]. A mean
change of 4.7 ± 7.5 seconds in 4SC time at week 48
was demonstrated in patients aged ≥7 years treated with
glucocorticosteroids (placebo arm) [27]. This difference is
greater than the minimal clinically important difference, i.e.,
clinically meaningful value of 2.1–2.2 seconds for 4SC
calculated by McDonald et al. [41]. An assumed change of
2.5 seconds (as determined a priori) from baseline in the
4SC time in patients treated with domagrozumab vs placebo
may suggest both a statistically significant and clinically
meaningful change.
Although neither muscle volume nor muscle volume index
measures were statistically significant in this study, they are
both consistent with a potential anabolic effect. The measure
of muscle volume index is of particular interest in patients
with DMD, because as the disease progresses, the percent
of total muscle volume decreases, whereas fatty replacement
of the muscle increases [30]. This study confirms the ability
to obtain reproducible and valid thigh muscle volume and
muscle volume index measures in an international multicenter
trial in a DMD population.
Among PODCI subscales, mobility and function scores
can distinguish between functional milestones in patients with
DMD [23,42,43]. A difference was seen in the domains of

upper extremity and physical function core scale, transfer
and basic mobility core scale, pain/comfort core scale,
and global functioning scale. Although natural history data
suggest PODCI subscales scores, especially mobility-related,
can distinguish between functional milestones representative
of disease progression in patients with DMD [23,42], little
data exist with respect to responsiveness of PODCI scores to
treatment.
Total serum myostatin levels were increased with
domagrozumab treatment as the binding of myostatin to
domagrozumab serves to sequester myostatin. The binding
of an antibody to its ligand increases the total plasma
levels of the ligand; because the ligand takes on the
properties (distribution and clearance) of the free antibody
[44]. Total myostatin in the serum accounts for myostatin
bound to domagrozumab and free myostatin. Based on the
concentrations of domagrozumab in the serum, >95% of
serum myostatin was bound (derived from a PK/PD analysis
to be published elsewhere) and unable to interact with its
target receptor. The systemic exposures increased with each
domagrozumab dose escalation and systemic exposures were
consistent with the predictions in healthy volunteers [45,46].
Several points may be useful for interpretation of our
findings and for design of future studies. This was the first
trial of domagrozumab in patients, and the lack of data in
patients led to a complicated study design, which was difficult
to execute. The 4SC measure may not be an optimal primary
efficacy endpoint to assess treatment effect of myostatin
inhibition; as true for other functional measures in DMD,
4SC is affected clinically by other confounders (e.g., ankle
contractures and weight gain) and not solely related to muscle
strength. It does, however, reflect an activity important for
daily living. There is an emerging consensus that NSAA
may be the best outcome measure for ambulatory patients
with DMD [47-50]. However, the lack of efficacy in several
secondary function and biomarker endpoints is consistent with
the lack of efficacy in the 4SC measurement and suggests
that the selection of 4SC as the primary endpoint was not
the sole cause for the negative outcome in this trial. The 2year outcomes were compared with historical control group
as there was no true 2-year placebo group in this study, but
this allowed all patients with rare disease the opportunity to
receive an active drug. Also, despite using some functional
criteria to exclude outliers, a number of outliers were still
present. This, together with the non-random distribution of
missing the primary endpoint data, posed challenges for the
MMRM analysis.
In conclusion, domagrozumab was generally safe and well
tolerated in this population of patients with DMD. The phase
2 trial did not meet its primary efficacy endpoint. In addition,
the totality of evidence, including secondary endpoints, did
not support a significant treatment effect with domagrozumab,
which led to termination of both trials. The studies were not
terminated due to safety reasons.
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